Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    17438314 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice
Condition: Helicobacter Pylori
Intervention: Drug: PPI, amoxicillin, metronidazole and clarithromycin
2 Recruiting Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
Condition: Helicobacter Pylori Infection
Interventions: Drug: Reverse hybrid therapy;   Drug: Standard triple therapy
3 Completed Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori
Condition: Helicobacter Pylori Infection
Interventions: Drug: 5RA-5RCM;   Drug: 5RA-5RCT;   Drug: 10RCA
4 Unknown  14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication
Condition: Helicobacter Pylori Infection
Intervention: Drug: PPI, amoxicillin, metronidazole and clarithromycin
5 Completed Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-Controlled Trial
Condition: Helicobacter Pylori Infection
Intervention: Drug: Placebo amoxicillin pantoprazole clarithromycin tinidazole

Indicates status has not been verified in more than two years